Cepheid obtained clearance from the FDA for expanded claims for its Xpert Carba-R, which is designed to detect carbapenemase-producing gram-negative bacteria. The clearance enables the molecular test to be used for analyzing perirectal swab specimens, enabling test results to be used for therapeutic strategies for pure colonies.
FDA clears expanded claims for Cepheid's molecular test
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.